Barclays Has Lowered Expectations for CRISPR Therapeutics (NASDAQ:CRSP) Stock Price

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) had its price objective reduced by research analysts at Barclays from $59.00 to $55.00 in a research note issued on Wednesday, Benzinga reports. The brokerage presently has an "equal weight" rating on the stock. Barclays's price objective would indicate a potential upside of 8.44% from the stock's current price.

Other analysts have also issued research reports about the company. Cantor Fitzgerald reaffirmed a "neutral" rating on shares of CRISPR Therapeutics in a research note on Thursday, August 8th. StockNews.com raised shares of CRISPR Therapeutics to a "sell" rating in a research note on Tuesday, October 29th. Chardan Capital decreased their target price on shares of CRISPR Therapeutics from $112.00 to $94.00 and set a "buy" rating on the stock in a research report on Tuesday, August 6th. Truist Financial reduced their price objective on CRISPR Therapeutics from $120.00 to $100.00 and set a "buy" rating on the stock in a research note on Monday, August 12th. Finally, Royal Bank of Canada lowered their target price on CRISPR Therapeutics from $60.00 to $53.00 and set a "sector perform" rating for the company in a research note on Friday, October 4th. Three analysts have rated the stock with a sell rating, eight have issued a hold rating and nine have issued a buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus target price of $74.94.

CRISPR Therapeutics Trading Up 0.7 %

Shares of CRISPR Therapeutics stock traded up $0.36 during trading on Wednesday, hitting $50.72. The stock had a trading volume of 2,276,440 shares, compared to its average volume of 1,455,793. The firm has a market cap of $4.31 billion, a price-to-earnings ratio of -15.48 and a beta of 1.67. CRISPR Therapeutics has a 12 month low of $43.42 and a 12 month high of $91.10. The business's 50-day moving average is $47.22 and its 200 day moving average is $52.25.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last issued its quarterly earnings results on Tuesday, November 5th. The company reported ($1.01) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.42) by $0.41. The business had revenue of $0.60 million for the quarter, compared to the consensus estimate of $6.65 million. During the same quarter last year, the business posted ($1.41) EPS. As a group, equities analysts expect that CRISPR Therapeutics will post -5.57 EPS for the current year.

Insider Transactions at CRISPR Therapeutics

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 4,293 shares of the firm's stock in a transaction on Monday, October 14th. The stock was sold at an average price of $46.28, for a total transaction of $198,680.04. Following the completion of the transaction, the chief executive officer now owns 226,540 shares of the company's stock, valued at approximately $10,484,271.20. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In other news, CEO Samarth Kulkarni sold 4,293 shares of CRISPR Therapeutics stock in a transaction that occurred on Monday, October 14th. The shares were sold at an average price of $46.28, for a total transaction of $198,680.04. Following the completion of the transaction, the chief executive officer now directly owns 226,540 shares in the company, valued at approximately $10,484,271.20. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, General Counsel James R. Kasinger sold 1,089 shares of the company's stock in a transaction that occurred on Monday, October 14th. The stock was sold at an average price of $46.28, for a total value of $50,398.92. Following the completion of the sale, the general counsel now owns 62,597 shares in the company, valued at $2,896,989.16. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 4.10% of the company's stock.

Institutional Trading of CRISPR Therapeutics

Several institutional investors have recently bought and sold shares of CRSP. Global Trust Asset Management LLC lifted its stake in shares of CRISPR Therapeutics by 150.0% in the second quarter. Global Trust Asset Management LLC now owns 500 shares of the company's stock worth $27,000 after buying an additional 300 shares in the last quarter. Larson Financial Group LLC lifted its position in CRISPR Therapeutics by 95.5% in the 2nd quarter. Larson Financial Group LLC now owns 565 shares of the company's stock valued at $31,000 after acquiring an additional 276 shares in the last quarter. GPS Wealth Strategies Group LLC boosted its stake in CRISPR Therapeutics by 99.7% during the 2nd quarter. GPS Wealth Strategies Group LLC now owns 615 shares of the company's stock valued at $33,000 after purchasing an additional 307 shares during the last quarter. Itau Unibanco Holding S.A. bought a new stake in shares of CRISPR Therapeutics in the 2nd quarter worth $35,000. Finally, Denver PWM LLC purchased a new position in shares of CRISPR Therapeutics in the second quarter worth $45,000. 69.20% of the stock is owned by hedge funds and other institutional investors.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.